無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

尋常性座瘡 (にきび) :主要19ヶ国の市場予測 (2018〜2028年)

EPIOMIC EPIDEMIOLOGY SERIES: ACNE VULGARIS FORECAST IN 19 MAJOR MARKETS 2018-2028

発行 Black Swan Analysis 商品コード 408555
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.91円で換算しております。
Back to Top
尋常性座瘡 (にきび) :主要19ヶ国の市場予測 (2018〜2028年) EPIOMIC EPIDEMIOLOGY SERIES: ACNE VULGARIS FORECAST IN 19 MAJOR MARKETS 2018-2028
出版日: 2018年07月01日 ページ情報: 英文 84 Pages
概要

尋常性挫創 (にきび) は慢性の皮膚炎症疾患で、どの年代にも発症しますが、特に若年層が多くなっています。主な症状や併存症として、ホルモンバランスの乱れや瘢痕の発生などがあります。

当レポートでは、世界の主要19ヶ国における尋常性挫創 (AV) の発症状況について分析し、疾患の概要や現時点での有病者数、性別・年代別 (5歳区切り) の詳細状況、地域別・民族別傾向、リスク要因、疾患の診断と予後、主な症状や合併症、将来的な動向見通し (今後10年間分) といった情報を取りまとめてお届けいたします。

目次

  • 図表一覧
  • イントロダクション
  • 疾患の原因
  • 危険因子と予防法
  • 疾患の診断
  • 地域別/民族別の差異
  • 疾患の予後と臨床経過
  • 疾患に関連する主な併存症/特徴
  • 患者数の定量化の手法
  • 尋常性挫創の最大有病者数
  • 尋常性挫創の特徴
    • 分類、重症度、徴候、病変の位置など
  • 尋常性挫創の主な併存症
  • 参考文献
  • 付録

分析対象国一覧

  • 米国、カナダ、フランス、ドイツ、イタリア、スペイン、英国、ポーランド、オランダ、ロシア、トルコ、日本、中国、韓国、インド、オーストラリア、ブラジル、メキシコ、アルゼンチン
目次
Product Code: ACVG0020718

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Acne Vulgaris in 19 Major Markets

Acne, or Acne Vulgaris (AV), is a chronic inflammatory disease of the pilosebaceous unit. Although acne can develop at any age, it most commonly affects adolescents and is triggered by the overproduction of sebum in the sebaceous glands. Acne vulgaris is characterised by presence of comedones, papules, pustules, cysts, nodules and, occasionally, scars. It can affect the face, anterior chest and upper back.

This report provides the current prevalent population for Acne Vulgaris across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, main classes of the disease by severity, type and grade, as well as disease aetiology, manifestations and co-morbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Acne Vulgaris include:

Underlying hormone imbalance

Puberty

Family history

Skin scarring

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Able to quantify patient populations in global Acne Vulgaris market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of Acne Vulgaris and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on Acne Vulgaris prevalent population.

Identify sub-populations within Acne Vulgaris which require treatment.

Gain an understanding of the specific markets that have the largest number of Acne Vulgaris patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR ACNE VULGARIS
  • FEATURES OF ACNE VULGARIS PATIENTS
  • CLASSIFICATION
  • SEVERITY
  • SIGNS
  • LESION LOCATION
  • OTHER FEATURES
  • COMORBIDITIES OF ACNE VULGARIS PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Grading of acne vulgaris
  • Table 2. Prevalence of acne vulgaris, total (000s)
  • Table 3. Prevalence of acne vulgaris, males (000s)
  • Table 4. Prevalence of acne vulgaris, females (000s)
  • Table 5. Patients with acne vulgaris by type, total (000s)
  • Table 6. Patients with inflammatory acne vulgaris by subtype, total (000s)
  • Table 7. Patients with acne vulgaris by severity, total (000s)
  • Table 8. Patients with acne vulgaris by severity grade, total (000s)
  • Table 9. Acne vulgaris patients with nodules, total (000s)
  • Table 10. Acne vulgaris patients with comedones, total (000s)
  • Table 11. Acne vulgaris patients with pustules, total (000s)
  • Table 12. Patients with acne vulgaris by severity of skin oiliness, total (000s)
  • Table 13. Acne vulgaris patients with scarring, total (000s)
  • Table 14. Acne vulgaris patients with ice pick scarring, total (000s)
  • Table 15. Acne vulgaris patients with hypertrophy scarring, total (000s)
  • Table 16. Acne vulgaris patients with atrophy scarring, total (000s)
  • Table 17. Acne vulgaris patients with lesions on the cheeks, total (000s)
  • Table 18. Acne vulgaris patients with lesions on the forehead, total (000s)
  • Table 19. Acne vulgaris patients with lesions on the mandible, total (000s)
  • Table 20. Acne vulgaris patients with lesions on the chin, total (000s)
  • Table 21. Acne vulgaris patients with lesions on the nose, total (000s)
  • Table 22. Acne vulgaris patients with lesions on the neck, total (000s)
  • Table 23. Acne vulgaris patients with lesions on the back, total (000s)
  • Table 24. Acne vulgaris patients with lesions on the chest, total (000s)
  • Table 25. Acne vulgaris patients with lesions on other body parts, total (000s)
  • Table 26. Acne vulgaris patients with physiological acne, total (000s)
  • Table 27. Acne vulgaris patients with premenstrual flare, females (000s)
  • Table 28. Acne vulgaris patients with hyperplasia, total (000s)
  • Table 29. Acne vulgaris patients with hyperplasia by type, total (000s)
  • Table 30. Patients with acne vulgaris by propionibacterial resistance, total (000s)
  • Table 31. Acne vulgaris patients with a family history of the disease, total (000s)
  • Table 32. Acne vulgaris patients with depression, total (000s)
  • Table 33. Acne vulgaris patients with polycystic ovary syndrome, females (000s)
  • Table 34. Abbreviations and acronyms used in the report
  • Table 35. USA prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 36. USA prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 37. Canada prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 38. Canada prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 39. France prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 40. France prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 41. Germany prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 42. Germany prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 43. Italy prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 44. Italy prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 45. Spain prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 46. Spain prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 47. UK prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 48. UK prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 49. Poland prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 50. Poland prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 51. Netherlands prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 52. Netherlands prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 53. Russia prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 54. Russia prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 55. Turkey prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 56. Turkey prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 57. Japan prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 58. Japan prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 59. China prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 60. China prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 61. South Korea prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 62. South Korea prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 63. India prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 64. India prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 65. Australia prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 66. Australia prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 67. Brazil prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 68. Brazil prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 69. Mexico prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 70. Mexico prevalence of acne vulgaris by 5-yr age cohort, females (000s)
  • Table 71. Argentina prevalence of acne vulgaris by 5-yr age cohort, males (000s)
  • Table 72. Argentina prevalence of acne vulgaris by 5-yr age cohort, females (000s)
Back to Top